Company profile
Opthea company profile
Opthea Limited (formerly Circadian Technologies) is a public Australian biotechnology company developing novel biologic therapies for the treatment of eye diseases. Opthea's lead compound, OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD).
Business identity
- Website
- http://www.opthea.com/
- Contact email
- [email protected]
- Phone number
- +61398260399
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Founded
- 1984-01-01, Year
Headquarters
- Headquarters
- South Yarra, Victoria, Australia
- Postal code
- 3000
- Country code
- AU
- Continent
- Oceania